GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (NAS:BBIO) » Definitions » Return-on-Tangible-Asset

BridgeBio Pharma (BridgeBio Pharma) Return-on-Tangible-Asset : -117.16% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BridgeBio Pharma's annualized Net Income for the quarter that ended in Dec. 2023 was $-672.59 Mil. BridgeBio Pharma's average total tangible assets for the quarter that ended in Dec. 2023 was $574.08 Mil. Therefore, BridgeBio Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -117.16%.

The historical rank and industry rank for BridgeBio Pharma's Return-on-Tangible-Asset or its related term are showing as below:

BBIO' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -115.44   Med: -61.6   Max: -31.17
Current: -114.2

During the past 7 years, BridgeBio Pharma's highest Return-on-Tangible-Asset was -31.17%. The lowest was -115.44%. And the median was -61.60%.

BBIO's Return-on-Tangible-Asset is ranked worse than
82.58% of 1556 companies
in the Biotechnology industry
Industry Median: -40.005 vs BBIO: -114.20

BridgeBio Pharma Return-on-Tangible-Asset Historical Data

The historical data trend for BridgeBio Pharma's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Return-on-Tangible-Asset Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -47.53 -67.21 -67.31 -61.60 -115.44

BridgeBio Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -85.08 -94.07 -117.65 -128.23 -117.16

Competitive Comparison of BridgeBio Pharma's Return-on-Tangible-Asset

For the Biotechnology subindustry, BridgeBio Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BridgeBio Pharma's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Return-on-Tangible-Asset falls into.



BridgeBio Pharma Return-on-Tangible-Asset Calculation

BridgeBio Pharma's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-643.202/( (594.324+520.061)/ 2 )
=-643.202/557.1925
=-115.44 %

BridgeBio Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-672.592/( (628.091+520.061)/ 2 )
=-672.592/574.076
=-117.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


BridgeBio Pharma  (NAS:BBIO) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


BridgeBio Pharma Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BridgeBio Pharma (BridgeBio Pharma) Business Description

Traded in Other Exchanges
Address
3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Executives
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Frank Mccormick officer: Chairman of Oncology C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001
Randal W Scott director 171 MAIN STREET #225, LOS ALTOS CA 94022
Neil Kumar director, officer: See Remarks C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Brian C Stephenson officer: See Remarks 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Douglas A. Dachille director 175 WATER STREET, NEW YORK NY 10038
Andrew Lo director C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Ronald J Daniels director C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
James C Momtazee director 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Brent L Saunders director 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Andrea Ellis director C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
Richard H Scheller director, officer: See Remarks C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990

BridgeBio Pharma (BridgeBio Pharma) Headlines

From GuruFocus

Insider Alert: An Insider Just Sold BridgeBio Pharma Inc Shares

By GuruFocus Research GuruFocus Editor 05-20-2023